On January 20, 2022, Shandong Jerei Technology Co., Ltd. and Shandong Boan Bio-technology Co., Ltd. signed a strategic cooperation agreement at Jerei Industrial Park in Yantai, Shandong, marking a new step for Jerei in the pharmaceutical field, which is of far-reaching strategic significance. For Boan Bio, it will also be the beginning of digital transformation and innovative development.
Currently, biotechnology frontier technology continues to make significant breakthroughs, biotechnology innovation and further development has been inseparable from the deep integration of big data and artificial intelligence and other new generation of information technology. Under the support of automation, Internet of Things, artificial intelligence, big data and other digital technologies, global pharmaceutical manufacturing enterprises continue to innovate and develop, and digital transformation has become a necessary path for pharmaceutical manufacturing enterprises to enhance their innovative research and development capabilities, improve product quality, reduce operating costs, and create competitive advantages.
At the same time, in the band purchasing, generic drug consistency evaluation and other pharmaceutical new policy and the development of the digital industry forced, driven by the traditional pharmaceutical industry is rapidly approaching the digital, more and more pharmaceutical companies have been deeply aware of the digital transformation of the development of the enterprise's “powerful assist”.
Founded in 2013, Shandong Boan Biotechnology Co., Ltd (Boan Biotechnology) is a holding subsidiary of Greenleaf Pharmaceutical Group, specializing in the development of therapeutic antibodies, focusing on oncology, autoimmunity, ophthalmology and endocrine diseases. Currently, Boan Bio has built a portfolio of more than 10 innovative antibodies with international intellectual property rights protection and 7 biosimilars, and its first biosimilar product, Bevacizumab® (bevacizumab injection), has been launched in China. Boon Bio has a fully integrated industrial chain from antibody generation and lead optimizer, cell line establishment and process development, technology transfer, pilot production and commercialization. In addition to China, Boon Bio is also engaged in biopharmaceutical product development in the US and EU markets.
Shandong Jerei Digital Technology Co., Ltd. is a digital twin-driven industrial internet company. Relying on Fulima Cloud, it helps enterprises in digital transformation and empowers the digital transformation of manufacturing industry from the three dimensions of digital marketing, digital production and digital control.
With the signing of this strategic cooperation agreement, the two sides will take the demand of teaching and training, scientific research and other needs of the pharmaceutical industry as the starting point, and empower the digital transformation of the pharmaceutical industry as the goal, carry out in-depth exchanges and cooperation in the field of collaboration in virtual simulation technology and the construction of digital twins intelligent factories, as well as strengthen the content of the cooperation and enhance the value of the cooperation in the areas of publicity and promotion, product development, informationization and customer service, so as to promote the overall Pharmaceutical industry digital development and innovation.
Mou Wenqing, president of Jerei, said that the digital transformation of the pharmaceutical industry is a challenge and a rare opportunity. From the value level, the main goal of digital innovation in the pharmaceutical industry is to empower scientific research, reconfigure business operations and optimize user experience. Digital transformation can accelerate new drug research and development, improve production efficiency, reduce marketing costs, improve patient experience, and provide new momentum for the development of the entire pharmaceutical industry. The signing of this contract will be the beginning of complementary advantages and information sharing between the two parties. In the future, Jerei will also seize the opportunity to continuously improve the strength of science and technology innovation, further empower the development of the industry with digital technology, reshape the pattern of the pharmaceutical industry chain, and realize the comprehensive digitization of elements, processes, and services.
Jiang Hua, CEO of Boan Bio, said on the spot that in the post epidemic era, Boan Bio is deeply aware of the unsolvable problems in the traditional pharmaceutical industry chain, which can be empowered, reconstructed and optimized by digital technology to break down the barriers between traditional links. Only by carrying out digital transformation and taking advantage of favorable factors such as social cognitive change and policy promotion under the epidemic, can the enterprise accelerate its progress towards intelligence. The future cooperation with Jerei will start from teaching and training, with the help of virtual simulation technology, digital twin intelligent factory construction, effectively reduce production costs and market risks, and in the future, it will also penetrate into more segments, empowering innovation through digital transformation.
At the signing site, Zhang Zhenhua, president of the Yantai Municipal Committee of the Zhigong Party, dean of the School of Hydraulic Engineering of Ludong University and president of the Institute of Cross-Sea Engineering, Chen Haopeng, standing committee member of Laishan District, deputy mayor of Laishan District, and Wang Zhenjie, deputy director of science and technology of Yantai Hi-tech Zone Management Commission, and other leaders witnessed the signing of the strategic cooperation between the two sides and reported warm congratulations to the two enterprises on their cooperation, and hoped that both sides would speed up the pace of cooperation, seek common development, and give full play to It is hoped that both parties will accelerate the pace of cooperation, seek common development, give full play to their own advantages and industrial chain specialization, and contribute to the economic development of Yantai City with the best service and quality.
The signing of this strategic cooperation has built a platform for both parties to work together for development and win-win cooperation, and we believe that with the concept of sincere cooperation and mutual benefit, we will create a new miracle and future. Based on the current situation and problems of digitalization and automation in China's pharmaceutical manufacturing enterprises, Jerei will also improve the competitiveness of enterprises with digital technology according to the actual situation of pharmaceutical enterprises, and contribute more digital power to promote the operational upgrading of China's pharmaceutical manufacturing enterprises, the innovation of products and service models, and enhance the comprehensive competitiveness of the industry in the international arena.
